Inhibitor of anandamide uptake (IC50
= 17.3 μ
M) with little or no activity at CB1
, TRPV1 and FAAH. Intravenous administration inhibits limb spasticity in mice with chronic relapsing experimental allergic encephalomyelitis (CREAE).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from VCU-IPF
A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid.
Di Marzo et al.
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis.
Ligresti et al.
Activity of a novel anandamide analog suggests a non-CB1, non-VR1 site of action.
Griffin et al.
2001 Symposium on the Cannabinoids, International, 2001;